Phase 1 Open-Label Multicenter Dose Escalation Study of mRNA-2752 a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L IL-23 and IL-36? for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Lymphoma
    Metastatic Solid Tumor Malignancies
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Has histologically confirmed advanced or metastatic disease with at least 1 measurable lesion. 2) Dose Escalation/Confirmation: has disease progression after adequate standard of care therapies for metastatic disease that are known to confer clinical benefit, is intolerant to treatment, or refuses standard treatment (no limit to prior lines of therapy).

You may not be eligible for this study if the following are true:

  • 1) Has received prior systemic anti-cancer therapy including investigational agents within 5 halflives or 28 days of the start of study treatment, whichever is shorter. 2) Has received prior radiotherapy with a limited field of radiation within 2 weeks or with wide field of radiation or to more than 30% of the bone marrow within 4 weeks before the first dose of study treatment. 3) Has current or prior use of immunosuppressive medication within 14 days before the first dose of study treatment.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.